Allarity Therapeutics Reports Clear Clinical Benefits From Phase 2 Trial; Improves Cash Balance Of $14M And Equity Balances Of $15M; Withdraws From S-1

Benzinga05-15

- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved

- On Track to Regain Compliance with All Nasdaq Listing Requirements

- No Variable Priced Securities are Outstanding

- Warrant Overhang Near Elimination

- Allarity Withdraws its Form S-1

- Establishes Equity of $15 Million

- Cash Balance of $14 Million

Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435528322?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-15 04:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2435528322","market":"hk","top_or_hot":-1,"title":"Allarity Therapeutics Reports Clear Clinical Benefits From Phase 2 Trial; Improves Cash Balance Of $14M And Equity Balances Of $15M; Withdraws From S-1","media":"Benzinga","content":"<html><body><p><i>- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved</i></p><p><i>- On Track to Regain Compliance with All Nasdaq Listing Requirements</i></p><p><i>- No Variable Priced Securities are Outstanding</i></p><p><i>- Warrant Overhang Near Elimination</i></p><p><i>- Allarity Withdraws its Form S-1</i></p><p><i>- Establishes Equity of $15 Million</i></p><p><i>- Cash Balance of $14 Million</i></p><p><strong>Boston</strong> (May 14, 2024)—Allarity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (\"Allarity\" or the \"Company\") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allarity Therapeutics Reports Clear Clinical Benefits From Phase 2 Trial; Improves Cash Balance Of $14M And Equity Balances Of $15M; Withdraws From S-1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllarity Therapeutics Reports Clear Clinical Benefits From Phase 2 Trial; Improves Cash Balance Of $14M And Equity Balances Of $15M; Withdraws From S-1\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-15 04:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/24/05/38828167/allarity-therapeutics-reports-clear-clinical-benefits-from-phase-2-trial-improves-cash-balance-of><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved- On Track to Regain Compliance with All Nasdaq Listing Requirements- No Variable Priced Securities are Outstanding...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/24/05/38828167/allarity-therapeutics-reports-clear-clinical-benefits-from-phase-2-trial-improves-cash-balance-of\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EQR","symbol_name":"资产住宅公司","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/24/05/38828167/allarity-therapeutics-reports-clear-clinical-benefits-from-phase-2-trial-improves-cash-balance-of","article_id":"2435528322","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435528322","pubTimestamp":1715717365,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved- On Track to Regain Compliance with All Nasdaq Listing Requirements- No Variable Priced Securities are Outstanding- Warrant Overhang","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EQR":"资产住宅公司","PSQ":"纳指反向ETF","QID":"纳指两倍做空ETF","BK4585":"ETF&股票定投概念","ALLR":"Allarity Therapeutics Inc","BK4139":"生物科技","BK4215":"住宅房地产投资信托","BK4588":"碎股","LENZ":"Therapeutics","TQQQ":"纳指三倍做多ETF","QLD":"纳指两倍做多ETF",".IXIC":"NASDAQ Composite","SQQQ":"纳指三倍做空ETF","QQQ":"纳指100ETF"},"translate_title":"Allarity Therapeutics报告了2期试验的明确临床益处；将现金余额提高1400万美元，股权余额提高1500万美元；退出S-1","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1,"LENZ":1,"ALLR":0.9,".IXIC":0.68,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved- On Track to Regain Compliance with All Nasdaq Listing Requirements- No Variable Priced Securities are Outstanding- Warrant Overhang Near Elimination- Allarity Withdraws its Form S-1- Establishes Equity of $15 Million- Cash Balance of $14 MillionBoston (May 14, 2024)—Allarity Therapeutics, Inc. (\"Allarity\" or the \"Company\") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.1","shortVersion":"4.24.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435528322"}